Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Daratumumab with ATRA in R/R MM

Niels van de Donk • 7 Dec 2019
ASH 2019
Multiple Myeloma All-trans retinoic acid Antibodies Daratumumab
DARA/ATRA

Patients with multiple myeloma (MM) that develop bortezomib and lenalidomide-resistant disease have a median survival of 9 months; this clearly illustrates that new anti-MM approaches are needed. Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses the results of the phase I/II DARA/ATRA study (NCT02751255). This clinical trial assessed the efficacy and safety of daratumumab combined with all-trans retinoic acid (ATRA) in relapsed/refractory MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals